Insight
Women Who Lead: An interview with Malissa J. Wood, MD

By Women As One
Welcome to Women Who Lead, a series highlighting inspiring women leaders in cardiology who are shaping the future of cardiovascular medicine.
In this edition, we feature Dr. Malissa Wood, a distinguished cardiologist, physician executive, and champion for diversity and health equity.
Through her clinical leadership, programme-building, and advocacy, Malissa has advanced the care of women with cardiovascular disease while shaping more inclusive systems within medicine.
From founding landmark women’s heart health and SCAD programs to leading at the highest levels of organised cardiology, her work continues to strengthen opportunities for women physicians and improve health outcomes for women worldwide.
As Chief Medical Officer of Women As One, Dr. Wood leads the organisation’s medical and scientific activities, guiding clinical strategy, research, advocacy, and partnerships that advance equity for women in medicine.
What first drew you to cardiology, and what personal or professional experiences most shaped your leadership journey?
I was drawn to cardiology because it sits at the intersection of science, prevention, and human connection.
Early in my training, I became aware of how differently cardiovascular disease presents in women—and how often those differences were overlooked. That realisation shaped both my clinical focus and my leadership journey.
Professionally, stepping into roles where I could build programmes, mentor others, and address inequities—particularly in women’s heart health—made it clear to me that leadership is not about title, but about creating systems that serve people better.
Can you describe a defining moment when your leadership made a meaningful difference for a patient, colleague, or institution?
One defining moment was helping to establish a multidisciplinary women’s heart health programme at Massachusetts General Hospital in Boston.
Seeing improved outcomes for patients—and watching early-career clinicians grow into confident leaders within that programme—reinforced the power of intentional leadership. It reminded me that when you invest in people and structure, the impact multiplies far beyond any one individual.
How has the landscape for women leaders in cardiology changed since you began your career, and what still needs to shift?
There is far greater visibility of women leaders today than when I began my career, and conversations around equity are more open and data-driven.
That said, representation still drops off sharply at senior leadership levels, and women continue to shoulder disproportionate clinical, mentorship, and “invisible” work.
What still needs to shift is not just access, but accountability—ensuring that leadership pathways are transparent, equitable, and sustainable.
What are the most persistent challenges facing women cardiologists in your country or region today?
Persistent challenges include pay inequity, lack of sponsorship, inflexible career structures, and the ongoing tension between professional advancement and personal responsibilities. Many women also face burnout from being asked to “do more” without the authority or resources to truly lead. Addressing these challenges requires structural—not just individual—solutions.
What leadership pathways are there for women cardiologists in your region, and where are opportunities still lacking?
Leadership pathways exist through academic promotion, professional societies, clinical programme development, and industry or nonprofit partnerships. However, opportunities are still lacking in early sponsorship, formal leadership training, and access to high-visibility roles that lead to executive positions. Too often, women are prepared but not positioned.
How is women’s leadership in healthcare viewed in your region, and what progress or resistance have you seen?
Women’s leadership is increasingly recognised as essential to high-quality, patient-centred care. We’ve seen progress in representation and advocacy, but resistance still shows up subtly—through unconscious bias, uneven expectations, and slower advancement.
True progress comes when women’s leadership is normalised, not exceptionalised.
What role do institutions and male colleagues need to play to truly accelerate gender equity in cardiology?
Institutions must commit to equity as a core value, supported by data, resources, and measurable outcomes. Male colleagues play a critical role as sponsors—opening doors, amplifying voices, and challenging inequities when they see them.
Gender equity is not a women’s issue; it is a leadership and quality issue.
In your view, what is the most urgent unmet need for women in cardiology today?
The most urgent unmet need is sustainable leadership infrastructure—clear pathways, protected time, and support systems that allow women to lead without burnout. Talent is not the limiting factor; opportunity and structure are.
What advice would you offer to early-career women cardiologists who want to lead, but may be unsure how to start?
Start by leading where you are. Seek mentors and sponsors, say yes to opportunities that align with your values, and don’t wait to feel “ready.”
Leadership is a skill that develops through action. Most importantly, remember that your perspective matters—especially in shaping the future of cardiovascular care.
Women like Malissa J. Wood, MD exemplify the vital role of leadership in advancing gender equality in healthcare and improving outcomes for women with cardiovascular disease. Supporting women in cardiology is essential not only for fairness but for better science and patient care.
The Women Who Lead series aims to uplift talented women in cardiology, raising their international profile and inspiring the next generation of women in cardiology. Join the Women As One community, The Pulse, today.
Opinion
The NHS doesn’t have a productivity problem: It has a precision problem

By Dr Melinda Rees, CEO, Psyomics
Spend enough time in the NHS and you stop flinching at the word “productivity”.
You hear it in every strategy document, every board meeting, every government announcement.
And almost every time, it means the same thing: do more with less.
It’s the wrong framing.
After 25 years working in and around clinical services – from NHS leadership to service delivery in the independent sector to where I am building technology that works with NHS mental health services – I’d argue it’s part of why progress has been so hard to achieve and sustain.
Productivity in healthcare shouldn’t mean squeezing more out of an already over stretched workforce.
It should mean something more precise: delivering greater value per pound by protecting and deploying finite clinical expertise intelligently.
That distinction sounds subtle. In practice, it changes everything about how you approach the problem.
The demand side of this equation isn’t going to get easier.
Multi-morbidity is rising. Mental health need is growing. Cases are more complex, and patient expectations – rightly – are higher.
The assumption that we can recruit our way out of this is understandable but wrong.
Training pipelines take years. Financial resources are finite. Even in an optimistic scenario, workforce expansion alone doesn’t close the gap.
So, the real question isn’t how do we get more clinicians. It’s whether we’re deploying the ones we have with maximum precision.
And honestly, in most services, the answer is no.
- Clinical time – the most valuable finite resource in the system – is routinely lost to things that have nothing to do with clinical decision-making.
- Administration.
- Repetitive documentation.
- Poor workflow.
- Systems that don’t share information across boundaries.
- Inconsistent and variable clinical decision-making.
- Referrals that shouldn’t have reached a specialist clinic in the first place.
- Reactive care models that wait for deterioration rather than anticipating it.
- Gathering baseline information that could have been collected earlier, more consistently, and without the clinician in the room.
Meanwhile, the waiting list grows.
This isn’t a motivation problem or a workforce culture problem. It’s a system design problem.
And it’s solvable – meaningfully – if we’re willing to rethink how technology fits into the picture.
The challenge with digital implementation in the NHS has rarely been the technology itself – it’s been layering new tools onto processes that were already under strain.
A new system that digitises an inefficient workflow is still an inefficient workflow.
Real productivity gains come when technology is used to redesign how work actually happens – not just record it.
In practice, that means four things.
First, automating the tasks that don’t require clinical expertise – structured data capture, digital triage, standardised assessment pathways.
Every minute saved on documentation is a minute returned to care. At scale, those minutes add up fast.
Second, bringing patients into the process earlier.
When a patient contributes structured, meaningful information before their first appointment, the clinician and patient have a great head start.
Better routing, smarter questions, faster and safer decisions, quicker access to the right treatment.
Third, monitoring caseloads intelligently.
Utilising tools that flag deterioration or signal when a care plan needs to change, rather than waiting for a crisis to trigger a review.
Finally fourth, making sure every appointment actually advances care. That sounds obvious.
In practice, without recorded structured outcome data, it’s surprisingly hard to know.
None of this requires drastic AI transformation or futuristic promises.
Some of the biggest gains come from making simple workflow tasks consistent and seamless – the kind of unglamorous operational improvement that doesn’t make headlines but compounds quietly across thousands of patient interactions and increases productivity.
A 1-2 per cent productivity gain per clinician sounds modest.
At NHS scale, across millions of appointments, it isn’t. It’s the difference between a system grinding and one with genuine headroom to breathe.
It’s the difference between your close relative being able to get an appointment when they genuinely need one or languishing on a waiting list with little hope.
I think about this a lot through the lens of mental health services specifically, where I’ve spent most of my career and where Psyomics works.
Mental health has historically been underfunded and under-prioritised – something that disproportionately affects women, both as patients and as the clinicians and carers holding those services together.
The pressure to do more with less lands hardest here. And the argument that productivity means working harder is, in this context, particularly damaging.
Burnout in mental health services isn’t a footnote. It’s a crisis within a crisis.
The better argument – the one I’d like to see shape NHS policy – is that productivity means precision.
Precision in how we route patients. Precision in how we use structured data to reduce variation and improve decisions. Precision in how we protect clinical time for the work that only a skilled clinician can do and loves to do.
That’s not a technology story, exactly. It’s a system design story, in which technology plays an enabling role.
The NHS doesn’t need to do more with less.
The goal isn’t harder-working, exhausted clinicians – it’s smarter-working, compassionate enabled clinicians, and patients who are seen sooner.
Insight
Women’s health leaders warn of censorship
Features
Study reveals how oestrogen protects women from high blood pressure

Oestrogen helps protect premenopausal women from hypertension by relaxing and widening blood vessels, according to new research examining why women develop high blood pressure less often before menopause.
High blood pressure, also known as hypertension, affects more than a billion people worldwide and is a leading cause of heart disease and stroke.
Premenopausal women are less likely to develop the condition than men or postmenopausal women, but the biological reason has been unclear.
Researchers used a mathematical model of the cardiovascular and kidney systems to analyse how oestrogen influences blood pressure.
The analysis found that oestrogen’s strongest protective effect comes from vasodilation, the process by which blood vessels relax and widen, helping blood flow more easily and lowering pressure in the arteries.
Anita Layton, Canada 150 Research Chair Laureate in Mathematical Biology and Medicine and professor of applied mathematics, said: “Oestrogen is often thought of only in terms of reproductive health, but it plays a much broader role in how the body functions.
“It affects how blood vessels respond, how the kidneys regulate fluids and how different systems communicate with one another.
“What we found is that its impact on blood vessels is especially important for regulating blood pressure.”
The findings may also have implications for treating women after menopause, when oestrogen levels naturally decline.
The model predicted that angiotensin receptor blockers, a common class of blood pressure drugs, could be more effective than another widely used treatment group known as angiotensin converting enzyme inhibitors in treating women with hypertension, even after oestrogen levels decline after menopause.
Layton said her team has spent years developing a mathematical model of women’s kidneys and the cardiovascular system, designed to explore how different biological mechanisms affect blood pressure.
The model allows researchers to test individual effects separately and examine how each influences the body.
“We can turn on one effect, then another, and see exactly how each one affects the body,” Layton said.
She added: “For too long, women’s health, especially older women’s health, has been overlooked by medicine.
“Understanding how age and sex affect the body and, therefore, treatment, is an equity issue.”
Entrepreneur4 weeks agoUS startup builds wearable hormone tracker
Fertility4 weeks agoFrance urges 29-year-olds to start families now
Menopause4 weeks agoWomen with ADHD almost twice as likely to experience perimenopause symptoms, study finds
Entrepreneur4 weeks agoKindbody unveils next-gen fertility platform
Entrepreneur2 weeks agoOura launches women’s health AI model
Menopause4 weeks agoMenopause specialist Haver joins Midi Health
Opinion4 weeks agoThe $128b paradox: Corporate wellness vs women’s burnout
Entrepreneur4 weeks agoKate Ryder headlines Women’s Health Week USA 2026 as full agenda goes live














